Wellinks Closed $10 Million Series B Funding from UMass Memorial Health and inside investors

Wellinks, a leading provider in cardiopulmonary care, has announced the successful first close of its Series B funding round, securing $10 million in capital. This funding round, which took place on August 4, 2026, saw participation from UMass Memorial Health, further strengthening the strategic partnership between the two entities. The investment aims to support Wellinks' commercial growth and enhance its innovative predictive care model.

The funding will enable Wellinks to expand its commercial footprint and extend its cardiopulmonary care services to a broader and more diverse patient population, including those in rural and underserved communities. Wellinks is known for its FDA-cleared Spire Remote Patient Monitoring (RPM) System, which is designed to identify early physiological changes associated with clinical deterioration. This proactive approach allows for earlier intervention and improved management of chronic respiratory diseases, which is critical in a healthcare landscape increasingly focused on value-based care.

The collaboration between Wellinks and UMass Memorial Health has yielded significant results, particularly through their joint initiative, the Healthy at Home program. This program has demonstrated a remarkable reduction in acute care utilization among patients with chronic obstructive pulmonary disease (COPD), with participants experiencing over 60% lower odds of 30-day hospital readmissions. Such outcomes highlight the effectiveness of Wellinks' predictive care model and its potential to transform the management of chronic respiratory conditions.

The investment will also facilitate advancements in Wellinks' predictive capabilities by leveraging a growing body of real-world clinical data. This data-driven approach is expected to enhance decision support and further refine Wellinks' care solutions. Additionally, the company plans to expand its focus to other cardiopulmonary conditions, such as congestive heart failure (CHF), thereby broadening its impact on high-risk patient populations.

The implications of this funding round extend beyond Wellinks and UMass Memorial Health, reflecting broader trends in the healthcare sector. As the industry increasingly shifts towards proactive and data-driven care models, investments in innovative technologies like those offered by Wellinks are likely to gain momentum. This trend underscores the importance of addressing care gaps and improving health outcomes, particularly for underserved populations. As healthcare systems continue to seek solutions that reduce costs and enhance patient care, Wellinks' approach may serve as a blueprint for future developments in chronic disease management.